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 A modeling study on effective delivery of hyaluronan-cisplatin (HA-Pt) in 
human colorectal cancer was carried out. The main objective was to investigate how the 
HA-Pt conjugate improves drug delivery to colorectal cancer cells. The software, 
Discovery Studio 2.5 generates a three-dimensional simulation of the conjugated drug. 
The drug cisplatin is classified as an alkylating agent, the first platinum based anticancer 
drug that is effective against cancer. It inhibits DNA actual utilization by base pairing 
and causes a miscoding of DNA. Hyaluronan is a naturally occurring linear polymer that 
is a major component of extracellular matrix (ECM). The hyaluronan receptor, CD44 is 
overexpressed in cancer cells compared to normal cells. As a result, HA binding to 
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1.1 Background of study 
  
 Cancer evolution is a complex process that involves many different phenomena 
that occurs at different scales. The phenomenological description strongly depends on 
the enlargement used in real or ideal microscopic scale such as the nanoscale simulation. 
From the modeling point of view, a connection can be drawn between the cellular level 
and the microscopic, mesoscopic and macroscopic scales.  
As the factors that affect drug delivery are linked to biochemistry and 
metabolism taking place at the nanoscale in the body, nanotechnology holds better 
potential in overcoming problems related to drug delivery. It involves the intersection of 
variety of disciplines including engineering, material science, chemistry and physics 
with cancer biology (Mansoor, 2007). Nanotechnology enables the maintaining of drug 
level in therapeutic range, increasing specificity, sustained drug delivery and decreasing 
toxicity side effects. Knowledge in polymer chemistry is combined together in order to 
develop novel methods for drug delivery.  
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1.2 Problem Statement 
 
 Abnormal cell proliferation is what defines tumorigenesis. It is the increase in 
tumor cell number, and thus tumor burden that ultimately accounts for the adverse 
effects on the host. The objective of current cancer therapy is to reduce the number of 
tumor cells to prevent further accumulation. For this reason, the understandings of 
nanoscale drug delivery system to cancer cells play a significant role in improving 
cancer treatment. The interaction between anti-cancer drug towards the cancer cells 
should first be understood.  
Up to date, there are numerous available anticancer drugs with distinct 
mechanism of action. The effects they pose to the normal and cancer cells may vary 
from one drug to another. Besides that, the chosen drug may also face problem such as 
poor solubility, unsuitable retention time, poor bio compatibility or some other 
problems. As the drugs used to fight cancer affect normal cells as well as cancerous cell, 
treatment with these drugs must be balanced between maximum killing of cancer cells 
and minimum effect on normal cells. Therefore, improvement in drug delivery system is 
important to ensure high selectivity on cancer cells and decreasing negative side effects. 
 Molecular modeling combines the theoretical method and computational to 
mimic the behavior of the molecules in three dimensional manner. Some features of 
molecular modeling is that it allows structure optimization, energy minimization and 
molecular docking. In molecular docking, the software regonizes interaction between 
ligands and targets at atomic level. 
 In the past, the anti-cancer drugs development does not focus on macromolecular 
targeting. Currently, the development search for specific target that subsist in cellular 
compartments to assist treatment of cancer. Therefore, molecular modeling is used to 
explore such target to support experimental effort. Besides that, this method can also be 






The objectives of the project are: 
 To model the nanoscale drug delivery system to cancer cells using Discovery 
Studio 2.5.  
 To investigate the cisplatin mechanism of action towards cancer cells. 
 To simulate the delivery of hyaluronan-cisplatin conjugate to cancer cells by 
CD44 signaling pathway.  
 
1.4 Scope of Study  
  
The project comprises a study of molecular modeling to increase the solubility of 
anticancer drugs and CD44 mediated drug delivery. Assumptions are made and defined 
in order for the project objectives to be achieved in the time frame given.  
In the modeling framework, the assumptions were: 
 Hyaluronan-CD44 interaction follows the lock and key analogy  
 Cisplatin automatically released into cells after hyaluronan-CD44 interacts 
 Van de Waals forces can be ignored 
The modeling of this project focuses on three dimensional molecular modeling 
to produce hyaluronan-cisplatin conjugate. Prior to that, the properties and the reaction 
between hyaluronan-cisplatin, hyaluronan to CD44 and cisplatin to cancer cells must be 








2.1 Cancer cells 
 
Disregulation of cell proliferation and apoptosis are the hallmarks of cancer cells 
(Shi et al., 2006). Normal body cells grow and divide and know to stop growing. Over 
time, they also die. Unlike these normal cells, cancer cells just continue to grow and 
divide out of control and do not die when they are supposed to. In addition for 
regulation of cell proliferation, cell numbers are also controlled by regulated apoptosis 
(Shi et al., 2006).However, cancer cells have developed many kinds of mechanisms to 
be refractory to this regulatory signal and thus do not undergo apoptosis under 
appropriate conditions (Elliott & Blobe, 2005; Hanahan & Weinberg, 2000). The 
differences between a normal and cancer cells are shown in Figure 2.1. 
 




The changes in physical properties of the cells may be caused due to the reasons 
summarized as follows: 
 
 
Physical changes Explanation 
Cytoskeletal changes 
The distribution and activity of the microfilaments 
and microtubules may change and this allows the cell to 
interact with neighboring cells and alter the appearance 
of the cells. 
Cell adhesion/motility 
The reduction of cell to cell and cell to extracellular 
matrix adhesion allows large masses of cells to form. 
Nuclear changes 
The shape and organization of the nuclei of cancer cells 
may be markedly different from that of the nuclei of 
normal cells of the same origin. 
Enzyme production 
Cancer cells often secrete enzymes that enable them to 
invade neighboring tissues. These enzymes digest away 
the barriers to migration and spread of the tumor cells. 
 
  
Table 2.1: The changes in physical properties of cancer cells. (Changes 
in Physical Properties of Cancer Cells, 2010) 
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2.2 Cancer cell metabolism and proliferation 
 
Cancer cells show clear differences in energy metabolism when compared to 
normal cells. The metabolism of cancer is approximately 8 times greater than the 
metabolism of normal cells. The first tumor-specific alteration of altered metabolism 
was discovered by the Nobel Prize winner Otto Warburg in the 1920s (Kroemer & 
Pouyssegur, 2008). The ‘‘Warburg phenomenon’’ consists of an increase in glycolysis 
that is maintained in conditions of high oxygen tension (‘‘aerobic glycolysis’’) and 
gives rise to enhanced lactate production (Brahimi-Horn, Chiche, & Pouysségur, 2007; 
Warburg, Posener, & Negelein, 1930) 
 
Figure 2.2: Energy production through the breaking down of ATP molecule.  
(Source: http://www.atpdepletion.com/) 
 
All cells need energy to survive and divide. The energy is produced from the 
production on Adenosine Triphosphate (ATP) through glycolysis. Compared to normal 
cells, cancer cells need to generate ATP at a much higher rate which is required to 
synthesize new molecules and rapidly divide. For that reason, the energy metabolism of 
cancer cells are significantly altered and they generate an excessive amount of ATP.  
A normal cell is surrounded by a membrane which selectively allows materials 
to flow in and out. Oxygen and nutrients, such as glucose, flow in and the waste 
products of cellular chemistry flow out. The cells are protected by the immune system 
whereby a well functioning immune system is the best defence against the formation of 




However, when environmental toxins or carcinogens overpower the immune 
system, the entire program is altered. The cell membrane is affected first, losing its 
ability to exchange oxygen causing the cell to revert to a primitive survival mechanism 
which is fermentation. The newly formed anaerobic cancer cell cannot be repaired as 
fermentation is not reversible and the cell is now out of control and must be destroyed as 
rapidly as possible. 
 
Figure 2.3: Glycolysis and fermenatation. 
(Source: http://forums.studentdoctor.net/showthread.php?t=207239&page=4) 
 
The lactic acid produced by fermentation lowers the cell pH and destroys the 
ability of DNA and RNA to control cell division causing uncontrolled cancer cell 
multiplication. Unlike normal cell whose pH is 7.3 to 7.4, cancer cells have pH as low 
as 4.0 or 5.5 in the case for terminal cancer. Besides that, the charge of cancer cell drops 
from 90 milivolts to less than 40 milivolts causing only 5 substances that can pass in or 
out of the cell which are water, sugar, potassium, cesium and rubidium. Oxygen cannot 
enter the cell despite the large amount of oxygen in the blood. Cesium, because of its 
electrical properties can still enter the cancerous cell. Therefore, it is usually used in 
high pH therapy of cancer. Besides cesium, other strong alkaline that is mainly used to 









Cancer cells contain the full complement of biomolecules that are necessary for 
survival, proliferation, differentiation, cell death, and expression of many cell-type-
specific functions. Cancer happens when these functions are not properly regulated. 
Hence, to understand cancer, it is important to understand proliferation in normal cells 
and how it becomes uncontrolled in cancer cells. 
Fundamentally, accumulation of clonal cells causes cancer. Cell proliferation is 
an increase in the number of cells as a result of cell division. The rate of cell 
proliferation depends on three parameters:  
(a) Rate of cell division (Tc) referring to the time needed to complete cell division 
cycle 
(b) Fraction of cells within the population undergoing cell division 
(c)  Rate of cell loss from the population due to terminal differentiation or cell death  
In normal cell development, each organ maintains control over Tc, growth 
fraction and cell loss. Physiological stimuli can change these parameters leading to 
increased growth in tissues. However, a new steady state is achieved once the stimulus 
is removed. 
 The cell division cycle must be comprehended to know the defects that may have 
happen that cause abnormal proliferation process in cancer cells. Cancer cells tend to 
continuously grow and divide out of control while normal cell follows the cell division 





Figure 2.5: The cell division cycle. 
(Source: http://www.phschool.com/science/biology_place/biocoach/mitosisisg/cellcyc.html) 
 The cell division cycle consist of two major phase which is the interphase and 
mitosis phase. The interphase is the phase where the cell grows and replicates its DNA. 
It consists of 3 stages known as Gap 1 (G1), DNA synthesis (S) and Gap 2 (G2). The 
mitosis phase (M) is where cells divide into two cells that are identical to the mother 
cell. The functions of each stage are shown in Table 2.2. 
Table 2.2: The cell cycle functions. 
Phase Stage Description 
Interphase G1 Growth and preparation of the chromosomes for 
replication 
S DNA replication 
G2 Ensure cell is ready to enter M phase and divide 
Mitosis M Cell growth stops and cellular energy is focused on the 
division into two daughter cells 
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Tumor cells can proliferate without proliferation signals. Despite that, the tumor 
cells do not necessarily proliferate faster than normal cells. Biopsy samples from 
normal, inflammatory, and neoplastic lesions of the lung, cervix, vocal cord, or pharynx 
have been analyzed for the rate of cell proliferation. These studies show that benign 
inflammatory lesions can grow over 20 times faster than cancer in a discrete time and 
place (Teodori et al., 1990). Hence, not only rapid growth of cell distinguishes neoplasia 
but also uncontrolled growth over time.  
 The growth rate of cell decreases as the tumor mass increases. The change in 
growth rate with larger tumor may be caused by (Andreeff, Goodrich, & Pardee, 2000): 
 (a)  Decrease in the growth fraction 
(b)  Increase in cell loss  
(c)  Nutritional depletion of tumor cells resulting from outgrowth of available blood 
supply 
(d)  Lengthening of Tc 
However, the biochemistry of growth appears to be very similar qualitatively in 
tumor and normal cells (Weber, 1983). The fundamental difference probably lies in a 
relaxation of the regulation of cell growth (Fingert, Campisi, & Pardee, 1991).
 
For 
instance, proliferation of cancer cells still occurs in physiological level of growth factor 
whereby normal cells will remain inactive. Besides that, normal cell lies on secreted 
extracellular matrix (ECM) where various proteins stimulating cell growth present. 
Tumor cells however often are partly or completely independent of ECM for optimal 






2.3 Colorectal Cancer 
 
 Colorectal cancer is currently one of the most common cancers in Malaysia 
(Balraj & Ruhana, 2007). Based on the Malaysia Cancer Statistics 2006, in Peninsular 
Malaysia only, the colorectal cancer is the most common cancer among men and second 
most common among women. All in all, it is the second most common cancer after 
breast cancer in Peninsular Malaysia. A total of 2,866 cases were registered with 
National Cancer Registry in 2006, representing 13.2% of all cases registered.  
 
 
Figure 2.6: Ten most frequent cancer in Penisular Malaysia in 2006. 
(Sourcs: http://www.makna.org.my/PDF/MalaysiaCancerStatistics.pdf) 
 
Colorectal cancer is cancer that develops in the colon or the rectum. The colon 
and rectum are parts of the digestive system, also called the gastrointestinal system. The 
digestive system processes food for energy and rids the body of solid waste (fecal matter 





The colon consists of four sections which are the ascending colon, transverse 
colon, descending colon and sigmoid colon. Colorectal cancer usually develops slowly 
over a period of 10 to 15 years (Kelloff et al., 2004). Most of the colon cancers develop 
out of colon polyps, which grow like a mushroom out of the lining of the large bowel 
with a stalk and a fleshy polyp head. Certain kinds of polyps, called adenomatous 
polyps or adenomas, are the most likely to become cancers, though fewer than 10% of 
adenomas progress to cancer (Levine & Ahnen, 2006). 
 
Figure 2.7: Colon sections and colon polyp.  
(Source: http://www.medicinenet.com/colon_cancer/article.htm) 
 The extent to which colorectal cancer has spread is described by its stages. 




Figure 2.8: Stages of colorectal cancer. 
(Source: http://www.ipsas.upm.edu.my/caed/download/colon-ca.pdf) 
Table 2.3: Stages of colorectal cancer. 
Stage 0 The cancer is very early. It is found only in the innermost lining of 
the colon or rectum 
Stage I The cancer involves more of the inner wall of the colon or rectum. 
Stage II The cancer has spread outside the colon or rectum to nearby tissue 
but not to the lymph nodes.  
Stage III The cancer has spread to nearby lymph nodes but not to other parts 
of the body. 
Stage IV The cancer has spread to other parts of the body. Colorectal cancer 






2.4 Targeted Cancer Treatement 
  
  For decades, the hallmark of medical treatment for cancer has been intravenous 
cytotoxic chemotherapy (Gerber, 2008). This conventional chemotherapy typically 
works by killing rapidly dividing cells, which could be the tumor but also certain normal 
cells, causing side effects like hair loss, nausea, diarrhea and anemia (Pollack, 2010). 
Recent progress in understanding the molecular changes in cancer development offer the 
prospect of specifically targeting malfunctioning molecules and pathways to achieve 
more effective and rational cancer therapy (Sawyers, 2004). Targeted therapy may 
include monoclonal antibodies, small molecule inhibitors and targeted drug delivery.  
 Monoclonal antibodies are antibodies that are identical derived from one type of 
immune cell and each a clone of a single parent cell. In targeted cancer therapy, they are 
directed against molecules unique to, overexpressed in, or mutated in cancer cells. 
Monoclonal antibodies exert their anticancer effects through variety of mechanisms: by 
recruiting host immune functions (including natural killer cells and the complement 
cascade) to attack the target cell; by binding to ligands or receptors, thereby interrupting 
essential cancer cell processes; or by carrying a lethal payload, such as a radioisotope or 
toxin, to the target cell (i.e., conjugated monoclonal antibodies) (Gerber, 2008).  
Small molecule inhibitors typically interrupt cellular processes by interfering 
with the intracellular signaling of tyrosine kinases (Gerber, 2008). Tyrosine kinase 
signaling can lead to cell growth, proliferation, migration, and angiogenesis in normal 
and malignant tissues. Unlike monoclonal antibodies, small molecule inhibitors are 
usually administered orally rather than intravenously. 
 Some therapies take advantage of the features in cancer in order to develop 
targeted therapy. Most solid tumors possess unique features and defects of their 
associated vasculature, such as extensive angiogenesis, defective vascular architecture, 
and increased vascular permeability, all of which can be used for delivering therapeutics 
(Juillerat-Jeanneret, 2008). Recognizing these features allows the usage of 
functionalized drug colloidal carrier for targeted delivery of anticancer drugs to tissues. 
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This can be done passively by increasing vascular permeability in defined location or 
actively by chemically modified drugs or nanoparticle. Alternatively, direct modification 
and/or functionalization of drugs, involving the chemical conjugation of drugs to 
disease-targeting biological markers, can be used to achieve direct active targeting of 




2.5 Cisplatin  
 
In 1893, Alfred Werner suggests that Pt(NH3)2Cl2 actually consists of two 
isomers of square planar which is the cis-isomer namely cis- 
diaminedichloroplatinum (II) and trans-isomer also known as transplatin. In 1969, 
Barnett Rosenberg has shown that only the cis-isomer has antitumor activity and is now 
known as cisplatin in short. In contrast, even though transplatin produce the same 
complex with DNA, it does not have useful anticancer activity. The different geometries 
of these two isomers result in different binding modes with DNA (Trzaska, 2005). 
 
Figure 2.9: Molecular structure of cisplatin and transplatin. 
(Source: http://clipartist.net/2011/04/page/138/) 
Cisplatin, or cis-diaminedichloroplatinum(II) (cis-DDP), is an anticancer drug 
widely used to treat a variety of tumors, especially those of the testes, ovaries, head and 
neck (Comess & Lippard, 1993). At normal condition, cisplatin is found as a clear 
liquid. It is given to patient intravenously. For example, it may be introduced via drip 
infusion, central line or peripherally inserted central catheter (PICC) line. Central lines 
are typically inserted into a vein near the collar bone whereas PICC lines are inserted 
into a vein in the arm. 
The exact dosage of cisplatin given to a patient is different from one to another. 
It depends on many factors such as the person height, weight, general health, other 
health problems and also the type of cancer of the patient.  
Cisplatin is the first platinum-based drug that is developed for cancer treatment. 
Since the introduction, other platinum based drug such as carboplatin and oxaliplatin are 
introduced. Cisplatin is classified as an alkylating agent. It works by preventing the 
      Cisplatin                                              Transplatin 
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production of genetic material by the cell. This is done by forming links with the strands 
of DNA and by doing so it binds them together. This prevents the cell from reproducing.  
 
Figure 2.10: 3D structure of cisplatin.  
(Source: http://www.3dchem.com/molecules.asp?ID=214) 
Platinum atom = dark grey, Chlorine = green, 






2.6 Cisplatin Mechanism of Action 
 
  
Although the mechanism has not yet been fully elucidated, cisplatin is generally 
believed to kill cancer cells by binding to DNA and interfering with the cell's repair 
mechanism, which eventually leads to cell death (Trzaska, 2005). In studies of the 
mechanism of action of cisplatin, it has been known that the cytotoxicity of cisplatin 
arises from its capacity to damage DNA, resulting in cisplatin-DNA adducts (A. M. J. 
Fichtinger-Schepman, 1985; Takahara, Rosenzweig, Frederick, & Lippard, 1995; 
Huang, Zhu, Reid, Drobny, & Hopkins, 1995). The formation of these adducts cause the 
purines to become destacked and the DNA helix to become kinked. 
 




The mechanism of action of platinum-based anticancer drugs such as cis-
diamminedichloroplatinum(II), or cisplatin, involves three steps: cell entry, drug 
activation, and target binding. The drug first enters the cell by active uptake or passive 
 20 
 
diffusion. Inside the cell, cisplatin undergoes hydrolysis producing the highly reactive 
charged platinum complex [Pt(NH3)2ClH2O]
+
. Further hydrolysis displaces the 
remaining chloride ligand, and the platinum can bind to a second nucleotide base. The 
hydrolysis reaction occurs as the following equation: 







 + H2O  [Pt(NH3)2(H2O)2]
2+
 
This complex coordinates to DNA through the N7 atom of either a guanine or 
adenine base (Trzaska, 2005). There are many types of adducts that can be formed by 
cisplatin and DNA. The major intrastrand cross-links are formed at guanine and adenine 
sites and represent ~90% of total platinum adducts (Eastman, 1987; Reedijk, 1992; 
Bruhn, Toney, & Lippard, 2007; Sip & Leng, 1993). The adducts formed are 1,2-
intrastrand cross-links, where platinum coordinates to two adjacent guanine residues or 
an adjacent adenine and guanine (Takahara, Frederick, & Lippard, 1996). The most 
common adduct formed by reaction of activated cisplatin with DNA is the 1,2-d(GpG) 
cis-diammineplatinum(II) intrastrand cross-link, with 1,2-d(ApG) and 1,3-d(GpNpG) 
intrastrand cross-links being formed to a lesser extent (Ober & Lippard, 2008). 
 
Figure 2.12: Types of intrastrand adducts. 
(Source: http://www.narainsamy.com/cisplatin-molecule&page=3) 
 
Interstrand cross-links are formed between two guanine residues on opposite 
strands at d(GpC)·d(GpC) sites and represent 5–10% of total platinum adducts  
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(Hopkins et al., 1991). The remaining are other intrastrand cross-links, interstrand cross-
links, monofunctional adducts, or protein-DNA cross-links.  
 
Figure 2.13: Monoadduct, interstrand adduct and intermolecular adduct. 
(Source: http://www.narainsamy.com/cisplatin-molecule&page=3) 
 
All in all, the drugs enter the cell by diffusion or with the aid of a transporter, 
become activated by forming aqua complexes, and bind to nuclear DNA, which in 
eukaryotes is packaged in highly condensed chromatin structures comprising 
nucleosome building blocks (Ober & Lippard, 2008). The figure below summarized 
cisplatin mechanism of action. 
 
 





2.7 Hyaluronan  
 
Hyaluronan or hyaluronic acid was discovered in bovine vitreous humour by 
Meyer and Palmer in 1934. Hyaluronic acid (HA) is a naturally occurring polyanionic, 
polysaccharide that consists of N-acetyl-glucosamine and β-glucoronic acid (Brown & 
Jones, 2005). Hyaluronan is found in all tissues and body fluids of vertebrates as well as 
in some bacteria (Fraser & Laurent, 2003). Hyaluronan is a high-molecular-mass linear 
polymer found in the extracellular matrix, especially of soft connective tissues (Fraser & 
Laurent, 1992). It is most frequently referred to as HA due to the fact that it exists in 
vivo as a polyanion and not in the protonated acid form (Brown & Jones, 2005). 
 




Figure 2.16: Structure of hyaluronan sodium salt. 
(Source: http://www.buyersguidechem.de/AliefAus.php?pnumm=780708239236) 
 
Glucoronic acid      N-acetylglucosamine 
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HA is made by enzymes called hyaluronan synthases (HAS). HA is synthesized 
at the plasma membrane with the polymer being extended from the reducing end, which 
results in its extrusion from the cell surface. This is typical for glycosaminoglycans 
(Tolg, Hamilton, & Turley, 2004). HA dissolves in water to form a viscoelastic solution, 
with increasing concentration raising the solution viscosity (10 mg/ml has a viscosity 
5000x that of water) (Varti et al., 1999). The unique viscoelastic nature of HA along 
with its biocompatibility and non-immunogenicity has led to its use in a number of 
clinical applications, which include: the supplementation of joint fluid in arthritis, as a 
surgical aid in eye surgery, and to facilitate the healing and regeneration of surgical 
wounds (Fraser & Laurent, 2003). As a result of its inherent biocompatibility, 
biodegradability, and bioactivity, HA has proven to be a versatile molecule in both drug 




2.8 Hyaluronan-Cisplatin Conjugate 
 
 A conjugation of a drug with a polymer is called a ‘polymeric pro-drug’. The 
polymeric conjugates of drug possess some advantages compared to their low molecular 
weight precursors. The main advantages include: (1) an increase in water solubility of 
low soluble or insoluble drugs, and therefore, enhancement of drug bioavailability; (2) 
protection of drug from deactivation and preservation of its activity during circulation, 
transport to targeted organ or tissue and intracellular trafficking; (3) an improvement in 
pharmacokinetics; (4) a reduction in antigenic activity of the drug leading to a less 
pronounced immunological body response; (5) the ability to provide passive or active 
targeting of the drug specifically to the site of its action; (6) the possibility to form an 
advanced complex drug delivery system, which, in addition to drug and polymer carrier, 
may include several other active components that enhance the specific activity of the 
main drug (Khandare & Minko, 2006). 
Cisplatin (CDDP) administered intravenously can cause severe side effects 
including increased risks of leucopenia, nausea, anemia, acute nephrotoxicity, and 
chronic neurotoxicity (both hearing loss and nerve damage) (Carrick, Ghersi, Wilcken, 
& Simes, 2004). These undesirable side effects could cause the patient reluctant to 
complete their chemotherapy sessions or their decision to use less effective 
chemotherapeutic agents. In addition, untargeted chemotherapeutics will result in low 
drug concentration of drug that reaches the cancer cells. By the linkage of an anticancer 
drug on the HA chain, a more selective target and release of the chemotherapeutic agent 
to tumor cells can be achieved (Meo, 2008; Platt & Szoka, 2008).  
   Cisplatin conjugated to hyaluronan (HA) which is a highly biocompatible and 
nonimmunogenic polymer (Cai, Xie, Bagby, Cohen, & Forrest, 2008). A hyaluronan-
cisplatin (HA-Pt) conjugate may increase CDDP concentrations and decrease systemic 
toxicity. HA-Pt conjugates had high anti-tumor activity in vitro similar to the free drug. 
Pathology studies demonstrated that animals with HA-Pt treatment showed milder 
degenerative changes in livers, less congestion as well as necrosis in kidneys and 60% 
of the animal were completely cured of head and neck cancers (Cai et al., 2008). In 
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another study, the area-under-the-curve of cisplatin in the axially lymph nodes shows 
74% increase when injected with HA-Pt compared with normal cisplatin. 
Hyaluronan sodium salt is used as it is more water soluble compared to actual 
hyaluronan. HA sodium salt also reacts readily with chlorine in CDDP. One or more 
chlorides on CDDP can be hydrolyzed and then replaced by carboxylate(s) on HA. This 
reaction releases NaCI which is not harmful for the body system and produces HA-Pt 
conjugate. The resulting conjugate is referred to as HA–Pt for clarity, although the 
conjugate is Pt(NH3)2(H2O)OOC
–
HA (mixture of mono- and di-conjugates) (Xie et al., 
2010).  
 





 CD44 is a family of integral cell membrane glycoproteins, with multiple 
functions (Nair, 2006). CD44 is encoded by a single gene which is composed of at least 
20 exons (Man-Sun, 1997). The protein has many different forms, generated by 
alternative mRNA splicing and by post-translational modification, which may mediate 
different functions (Kennel, Lankford, Foote, Shinpock, & Stringer, 1993). The most 
abundant form of CD44, standard CD44 (CD44s), consists of an N-terminal signal 
sequence (exon 1), a Link-homology hyaluronan-binding module (exons 2 and 3), a 
stem region (exons 4, 5, 16 and 17), a single-pass transmembrane domain (exon 18) and 
a cytoplasmic domain (exon 20) (Thorne, Legg, & Isacke, 2004). 
 
Figure 2.18: (A) Genomic organization of CD44. The exons encoding the hyaluronan-
binding domain and transmembrane domain are cross-hatched and stippled, 
respectively. (B) mRNA splicing patterns in CD44. The standard form of CD44, CD44s, 
comprises exons 1-5, 16-18 and 20 (green). Most variant forms of CD44, CD44v, 
contain the standard exons with combinations of exons 6-15 (v1-v10) (orange). The 
inclusion of exon 19, normally absent in most CD44 transcripts, results in a CD44 short-
tail variant owing to use of an alternative translation stop codon. 
(Source: http://jcs.biologists.org/content/117/3/373.full) 
These proteins have been implicated in many biological processes, such as cell 
adhesion, cell substrate, cell to cell interactions, including lymphocyte homing 
haemopoiesis, cell migration and metastasis (Makrydimas, Zagorianakou, 
Zagorianakou, & Agnantis, 2003). In immunobiology, CD44 is a valuable marker for 
memory cells, since B-cell and T-cell activation in the immune response leads to high 
expression of CD44. When an antigen triggers the immune response and activates the T-
helper cells, CD44 activity is increased by upregulation. CD44 variant isoforms are 
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expressed on different types of normal cells. In addition some isoforms are 
overexpressed on tumor cells including breast, cervical, endometrial and ovarian cancer 
(Makrydimas et al., 2003). 
CD44 is a single pass transmembrane protein which has four functional domains.  
One of the extracellular domains interacts with the glycosaminoglycan hyaluronan of 
the matrix. This interaction is modulated by other lipids and accessory proteins that 
interact with the transmembrane domain of CD44.  The cytoplasmic domain interacts 
with the cytoskeletal proteins for transmission of signal. 
 
 
Figure 2.19: Schematic of CD44 molecule. (Gul-e-Saba, Abdah, & Abdullah, 2010)  
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2.10 HA-CD44 Interaction 
 
 Hyaluronan has six characterized surface receptors namely CD44, RHAMM, 
LYVE-1, HARE, layilin and Toll-4 (Tolg, Hamilton, & Turley, 2004; Ingber, 2006). 
Many physiological functions of HA are thought to relate to its molecular 
characteristics, including its physiochemical properties, its specific interactions with 
hyaladhereins, such as CD44 and RHAMM (receptor for HA-mediated motility), and its 
mediating effect on cell signalling and behavior (Toole, 2001).  
All CD44 isoforms exhibit HA-binding site in their extracellular domain, and 
thereby serve as a major cell surface receptor for HA (Underhill, 1992). Hyaluronan 
interactions with CD44 mediate at least three important physiological processes which 
are signal transduction, assembly of pericellular matrices, and receptor-mediated 
internalization (Knudson, Chow, & Knudson, 2002; Toole, 2001). 
CD44 is a single pass transmembrane protein which has four functional domains.  
One of the extracellular domains interacts with the glycosaminoglycan hyaluronan of 
the matrix. This interaction is modulated by other lipids and accessory proteins that 
interact with the transmembrane domain of CD44.  The cytoplasmic domain interacts 
with the cytoskeletal proteins for transmission of signal (Nair, 2006). 
CD44 receptor is expressed in both normal and tumor stem cells (displaying 
unique ability to initiate normal and/or tumor cell-specific properties) and CD44 has 
been suggested as one of the important surface markers for both normal stem cells and 
cancer stem cells (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003).  
HA conjugates, nanoparticles, and microspheres have been widely used in the 
delivery of therapeutics to metastatic tissues that overexpress CD44. This drug delivery 
strategy may allow a controlled release of the drug and a high targeting selectivity on 
tumor cells, increasing drug cytotoxicity and decreasing its undesirable side effects 




Figure 2.20: (a) Interaction of HA-drug with CD44 receptors on tumor cell, (b) cell 
absorbs molecule by engulfing it through the CD44 "door", (c) HA-drug degrades and 





2.11 Case Studies of Molecular Modeling 
 
 Molecular modeling is a computer based science of deriving, representing and 
manipulating the structure and reactions of molecules. Numerous software has been 
developed and different type of software may produce different output. Examples of 
molecular modeling softwares are COSMOS, CHARMM, Discovery Studio and 
AutoDock. Some of the techniques applied in molecular modeling includes molecular 
visualization and molecular mechanics methods. 
An example of a work based on molecular modeling is the application of 
molecular dynamics simulation to predict the compatibility between water-insoluble 
drugs and self-associating poly(ethylenapplication of molecular dynamics simulation to 
predict the compatability between water-insoluble drugs and self-associating 
poly(ethylene oxide)-b-poly(ε-caprolactone) block copolymers. All the molecular 
modeling simulations were performed using the Material Studio software package 
running on Silicon Graphics (SGI) workstation cluster. Molecular dynamics (MD) 
simulation was applied to study the solubility of two water-insoluble drugs, fenofibrate 
and nimodipine, in a series of micelle-forming PEO-b-PCL block copolymers with 
combinations of blocks having different molecular weights (Patel, Lavasanifar, & Choi, 
2008). By implementing the Flory-Huggins interaction parameter in the simulation, the 
final results are proven to be consistent with the solubility data of the drug/PEO-b-PCL 
systems. 
Material Studio is also used in a case study of molecular modeling of gel 
nanoparticles with cyclosporine A for oral drug delivery. The Flory-Huggins theory as 
implemented in Material Studio modeling environment was used to study the interaction 
between cyclosporine A with different surfactants (Tokarsky, Andrysek, & Capkova, 
2011). Finally, structural parameters and energy characteristics of all systems have been 





Figure 2.21: Example of result using Material Studio. 
(Source: http://www.sciencedirect.com/science/article/pii/S0378517311002432) 
  
Another type of molecular modeling is using QSAR which could also stand for 
an approach of quantitative structure-activity relationship. It correlate the chemical 
structure with a defined process such as activity or reactivity. The QSAR also support 
3D QSAR for molecular modeling. In University of Helsinki, the researcher in drug 
delivery and pharmaceutical nanotechnology group uses QSAR for structure based 
models for oral drug absorption. The study focuses on models for efflux transport and 
volume of drug distribution (University of Helsinki, 2010).  
 The next case study of molecular modeling is on ligand docking and binding site 
analysis. In structure-based drug design process, the docking and binding affinity 
complex of a small molecule to the binding site of receptor is very important. For a 
thorough understanding of the structural principles that determine the strength of a 
protein/ligand complex both, an accurate and fast docking protocol and the ability to 
visualize binding geometries and interactions are mandatory (Seeliger & Groot, 2010). 
Hence, Autodock Vina is used to demonstrate the how docking and visualization can 









  In a study of computational approach for the identification of anti-HIV 
phytocompoun with respect to T-cell receptor through molecular docking, a 
combination of software were used including Discovery Studio. Discovery Studio is 
used for docking and ligand preparation. Molecular mechanics like scoring function 
which includes terms of hydrogen bonds is employed by DS to rank the docked posses 
(Daisy, Rajalakshmi, Lilly, & Anusta, 2011). In ligand preparation, hydrogen bonds 
were added to the three dimensional phytocompound and energy was minimized using 
CHARMm force field. Lipinski’s properties like molecular weight, log P and number of 
Hydrogen-bond donors and acceptors for the active principles were also noted. 
 
Figure 2.23: Different interaction of drug-receptor complex. The complexes are a) 
costunolide b) gymnemic diacetate with T-cell receptor. 
(Source : http://derpharmachemica.com/vol3-iss3/DPC-2011-3-3-18-31.html)  
Figure 2.22: Autodock grid maps displayed with different contour levels. a Map 
for interactions of aliphatic carbon atoms at contour level 5kcal/mol. b Same 
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Literature review on nanoscale drug delivery to 
cancer cells and drug modeling  
 
Discovery Studio Tutorial 
Modeling by Discovery Studio 2.5 tutorial CD. 
 
Modeling of Case Study 
Execute uni-molecular and multi-molecular modeling 
of case study. 
 
Result Analysis 
Interpret result and analyze the outcome by 
comparing it with theory. 
 
Analysis 
Documentation of Project Results 





Figure 3.1: Project flow chart. 
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Preliminary research involved a thorough literature review drawn from all 
aspects of the project. This enables complete understanding of the nature of the project 
and what can be manipulated to get the end results. Next, as Discovery Studio 2.5 is a 
new program purchased, the program must be studied and familiarized. In 
accomplishing this, a tutorial for the program is installed and studied. After 
understanding the project and the program, the three dimensional molecular modeling 
can be carried out. The modeling phase consists of two phase namely uni-molecular 
modeling and multi-molecular modeling.  
In uni-molecular modeling, the molecules of hyaluronan, cisplatin and CD44 are 
prepared based on their molecular structure identified through literature. After that, the 
interaction between the molecules are identified and studied in order to proceed to the 
multi-molecular modeling phase.  
 
            
 
  
Figure 3.2: Structure involved in uni-molecular modeling:  
A) Hyaluronan, B) Cisplatin and C) Schemetic of CD44 
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After identifying the active side of hyaluronan and cisplatin, the modeling for 
hyaluronan-cisplatin was prepared using Discovery Studio 2.5. The interaction between 
hyaluronan and CD44 are also modeled out.  
 
Figure 3.3: Hyaluronan-cisplatin 2D structure. 
The result from the molecular modeling was then compared with the theory 
drawn out through literature review in the result analysis step. If the result contradicted 
the theory, it must be analyzed again and the problems must be identified so that 






























3.3 Tools and Equipment 
 
For this project, the main tool required is Discovery Studio produced by 
Accelrys. This program is a software suite of life science molecular design solutions for 
computational chemists and computational biologists. Some of the main modeling that 
will help in this project is molecular and protein modeling. Besides that, the Discovery 
Studio Integrated QASR and Library Design tools will also be very helpful as it could 
quickly uncover compounds that have the greatest potential of becoming of new drugs.  
 
For all modeling software, a basic procedure will be applied. During the earlier 
stage, the geometry and parameters of the problem must first be identified. Next, the 
physically modeling will take place. The modeling result is to correspond to the case 









RESULTS AND DISCUSSION 
 
4.1 Modeling of Cisplatin 
 CDDP is a square planar molecule that exists in cis and trans form. Unlike 
cisplatin, transplatin does not function for anticancer drugs. Some of the reasons are 




 with N-Pt-N angle of 97 has lower enegery than trans 
form with N-Pt-N angle of 180 (Li & Jena, 2011). The rotation barrier to change N-Pt-N 




 reacts with 
two Guanines in DNA, the two N atoms in Guanines can readily bind to the Pt atom in 
cisplatin. However, transplatin does not provide this opportunity due to steric reasons 
(Li & Jena, 2011). As a result, it has faint cytotoxicity effect because of its geometry 
allowing less adduct formation with DNA if compared to the cis form.   
        
                     
Cisplatin is classified as an alkylation agent defined as a compound capable of 
covalently binding an alkyl group to a biomolecule under phsyiological conditions 
(aqueous solution, 37°C, pH 7.4) (Avendano & Menendez, 2008). DNA alkylating 
agents interact with resting and proliferating cells in any phase of cell, but they are more 
Figure 4.1: Cisplatin and transplatin. 
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cytotoxic during the late G1 and S phases (as mentioned). Before cisplatin reacts with 
DNA, two chlorine atoms is eliminated when attacked by water molecules. Therefore, 




. The modeling data of cisplatin 
can be referred below. 
 
Figure 4.2: Cisplatin with each atom numbered. 
Table 4.1: Bond and length of cisplatin. 
No Bond Length 
1 Pt1- N2 2.0036 
2 N2- H3 1.0299 
3 N2- H4 1.02943 
4 N2- H5 1.02965 
5 Pt1- N6 2.00446 
6 N6- H7 1.02941 
7 N6- H8 1.02974 
8 N6- H9 1.02945 
9 Pt1- Cl10 2.30145 
10 Pt1- Cl13 2.3007 
 
Average bond length = 1.478779 
In plasma, the high concentration of chloride prevents its hydrolysis, but when it 
enters the cell the much lower chloride concentration prompts its reaction with water to 
 40 
 
give the positively charged species. The active complexes enter the nucleus and become 
attracted by the negatively charged DNA. The antitumor properties of cisplatin are 
attributed to the kinetics of its chloride ligand displacement reactions leading to DNA 
crosslinking activities causing DNA bending and interfering with DNA replication, 
transcription and other nuclear functions and arresting cancer cell proliferation and 
tumor growth. Other mechanisms of cisplatin cytotoxicity include mitochondrial 
damage, decreased ATP activity, and altered cellular transport mechanisms. It was early 
checked that the cisplatin-DNA adducts were stable for at least three days at 37°C after 
their formation. 
 
Figure 4.3: Intracellular bioactivation of cisplatin. 
(Soure: http://www.scribd.com/doc/11639473/Medicinal-Chemistry-of-Anticancer-
Drugs) 
In cisplatin, there are two types of ligands which are the leaving ligands and the 
non-leaving ligands. It was established that amine ligands are the non-leaving ligands. 
Leaving ligands are usually anions of medium stability, and their replacement can take 
place on physiologically and therapeutically useful scale. A number of best leaving 
ligand are halogenides, carboxylates, sulphates, water and hydroxo ligand. Hydroxo 
ligand is important as in can increase the low solubility of platinum complexes in 
aqueous solution (Ašperger, 2003). It is a poorly soluble compound, maximum 




The chemical stability of cisplatin is adversely affected by pH and light. 
Cisplatin is unstable in aqueous solution unless chloride ions are present in sufficient 
concentration. The optimum pH for stability is within the range 3.5–5.5 (Williams, 
1990). Cisplatin is also relatively sensitive to light (Zieske et al., 1991). Degradation 
occurred during exposure to short-wavelength (350-490-nm) visible light (Zieske et al., 
1991). 
 






4.2 Modeling of Hyaluronan 
 
 
Figure 4.5: Hyaluronan. 
Hyaluronan (HA) is a linear polysaccharide of high-molecular by alternating 
addition of glucoronic acid and N-acetylglucosamine to the growing chain using their 
activated nucleotide sugars as subtrates. The number of repeat disaccharides in a 
completed hyaluronan molecule can reach 10 000 or more, a molecular mass of 4 
million Daltons (Necas, Bartosikova, Brauner, & Kolar, 2008). An average disaccharide 
has a length of 1nm. Hence, a hyaluronan molecule of 10 000 repeats could extend 
10μm  if stretched from end to end, a length approximately equal to diameter o a human 
erythrocyte (Cowman & Matsuoka, 2005). The modeling data of hyalutonan can be 




Figure 4.6: Hyaluronan with each atom numbered. 
Table 4.2: Bond and length of hyaluronan. 
No Bond Length  No Bond Length 
1 C1 - O2 1.43753  26 C1 - C24 1.53903 
2 O2 - C3 1.43433  27 C24 - O25 1.42748 
3 C3 - C4 1.5338  28 O25 - H26 0.988526 
4 C4 - C5 1.54146  29 C4 - N27 1.44567 
5 C5 - C6 1.56386  30 N27 - H28 0.993596 
6 C6 - C1 1.56423  31 N27 - C29 1.33488 
7 C1 - O2 1.48894  32 C29 - O30 1.23673 
8 O2 - C3 1.48694  33 C29 - C31 1.49486 
9 C3 - C4 1.57292  34 C31 - H32 1.09977 
10 C4 - C5 1.54096  35 C31 - H33 1.09927 
11 C5 - C6 1.55293  36 C31 - H34 1.09947 
12 C6 - C1 1.52777  37 O8 - H35 0.989564 
13 C1 - C7 1.49645  38 C24 - H36 1.09841 
14 C7 - O8 1.39092  39 C24 - H37 1.09886 
15 C7 - O9 1.23592  40 C1 - H38 1.09931 
16 C6 - O10 1.42946  41 C6 - H39 1.09844 
17 C5 - O11 1.42497  42 C5 - H40 1.09099 
18 O11 - H12 0.989177  43 C3 - H42 1.09833 
19 C4 - O13 1.42844  44 C3 - H68 1.09909 
20 O13 - H14 0.989262  45 C3 - H43 1.09787 
21 C3 - O15 1.53745  46 C4 - H44 1.099 
23 O15 - C5 1.46808  47 C5 - H45 1.09076 
24 C6 - O22 1.43051  48 C6 - H46 1.09841 




Average bond length = 1.290528 
Hyaluronan is degraded by a family of enzymes called hyaluronidases. Some of 
hyaluronidases are hyase, β -D-glucuronidase and β-N-acetyl-hexosaminidase. In 
general, hyase cleaves high molecular weight HA into smaller oligosaccharides while β 
-D-glucuronidase and β-N-acetyl-hexosaminidase further degrade the oligosaccharide 
fragments by removing nonreducing terminal sugars (Leach & Schmidt, 2004). The 
degradation products of HA, oligosaccharides and very low molecular weight 
hyaluronan exhibit pro-angiogenic properties (Mio & Stern, 2002). 
Jansen et al. (2004) investigated the possible cytotoxic effects, biocompatibility 
and degradation of hyaluronan based conduit for peripheral nerve repair. Based on this 
study, it was found that hyaluronan conduit is not cytotoxic and shows good 
biocompatibility. HA is highly non-antigenic and non-immunogenic, owing to its high 
structural homology across species and poor interaction with blood components 
(Amarnath, Srinivas, & Ramamurthi, 2006). In the body, HA occurs in salt form, 




4.3 Modeling of Hyaluronan-cisplatin 
 
 Hyaluronan-cisplatin is a drug conjugate to improve drug delivery system by 
implementing the CD44 receptor signaling. Besides that, the conjugate also is used to 
improve the properties of the free drug. The reaction to produce hyaluronan-cisplatin is 
described as the figure below. 
 
Figure 4.7: Reaction to produce hyaluronan-cisplatin. 
From the reaction above, it can be seen that cisplatin reacts with hyaluronan salt 
to produce hyaluronan-cisplatin (HA-Pt) by releasing sodium chloride. Sodium 
hyaluronan is used instead of hyaluronan because it is more water soluble and reacts 
readily with cisplatin. From Figure 4, the red circle shows the reacted atom which is the 
chlorine from cisplatin and sodium from sodium hyaluronan. The platinum forms bond 





Figure 4.8: Hyaluronan-cisplatin conjugate with each atom numbered.  
Table 4.3: Bond and length of hyaluronan-cisplatin. 
No Bond Length  No Bond Length  No Bond Length 
1 Pt1-N2 2.00372  22 C1-C7 1.51446  43 C31-H33 1.10088 
2 N2-N3 1.0319  23 C7-O8 1.39882  44 C31-H34 1.09807 
3 N2-H4 1.02902  24 C7-O9 1.23623  45 C24-H36 1.09851 
4 N2-H5 1.02899  25 C6-O10 1.43006  46 C24-H37 1.0986 
5 Pt1-C17 2.30474  26 C5-O11 1.42505  47 C1-H38 1.09917 
6 Pt1-N8 2.00929  27 O11-H12 0.989215  48 C6-H39 1.09796 
7 N8-H9 1.03079  28 C4-O13 1.42579  49 C5-H40 1.09742 
8 N8-H10 1.02879  29 O13-H14 0.99098  50 C3-H42 1.09976 
9 N8-H11 1.03025  30 C3-O15 1.46198  51 C3-H68 1.09726 
10 C1-O2 1.4384  31 O15-C5 1.4863  52 C3-H43 1.09815 
11 O2-C3 1.43576  32 C6-O22 1.44277  53 C4-H44 1.09898 
12 C3-C4 1.5323  33 O22-H23 0.982757  54 C5-H45 1.10002 
13 C4-C5 1.55843  34 C1-C24 1.53603  55 C6-H46 1.09933 
14 C5-C6 1.56874  35 C24-O25 1.4292  56 C1-H47 1.0979 
15 C6-C1 1.5618  36 O25-H26 0.987727  57 O8-Pt1 1.97837 
16 C1-O2 1.45542  37 C4-N27 1.47688   
17 O2-C3 1.46922  38 N27-H28 0.994418   
18 C3-C4 1.5362  39 N27-C29 1.34271   
19 C4-C5 1.5367  40 C29-O30 1.23554   
20 C5-C6 1.52808  41 C29-C31 1.50135   
21 C6-C1 1.54337  42 C31-H32 1.10101   
 




 Cisplatin as a free drug has low solubility in water. Poor water solubility has 
always been one of the most fundamental problems in drug delivery (Patel, 2011). It is 
estimated that around 40% of drugs in the pipeline cannot be delivered through the 
preferred route or in some cases, at all owing to poor water solubility (Salata, 2004). 
Bioconjugates of low molecular weight hyaluronic acid with cytotoxic agents is 
designed to improve solubility of the cytotoxic agent and facilitate its intravenous 
administration (Brekke & Gubbe, 2008). As hyaluronan soluble in water, it indirectly 
increases the cisplatin solubility in water. This is important so that it can be passed in 
the bloodstream to deliver its function.  
 Although various water-soluble synthetic polymers have been exploited for 
conjugation of hydrophobic drugs, naturally occurring polymers with intrinsic cell 
specific binding capacity have tremendous potential as a target-specific drug carrier 
(Manju & Sreenivasan, 2011). For example, hyaluronic acid (HA), a naturally occurring 
polysaccharide composed of N-acetyl-d-glucosamine and d-glucuronic acid has a strong 
affinity with cell-specific surface markers such as CD44 (Maeda, Seymour, & 
Miyamoto, 1992). As CD44 is overexpressed cancer cells including colorectal cancer, 
malignant cells with high metastatic activities often exhibit enhanced binding and 
uptake of HA.  
CD44 signaling improves the drug delivery system through targeted delivery to 
cancer cells. By this method, higher accumulation of cisplatin on cancer cells can be 
achieved. As a result, cisplatin cytotoxicity to the cancer cell increases while the healthy 
cells that surround them remain untouched and unaffected by the therapy. Consequently, 
the side effects of cisplatin such as nausea, kidney toxicity, low white blood cells and 





Figure 4.9: Mono and di-hydrated cisplatin. 
 When HA is attached to the CD44 on its ligand, it will release a highly reactive 
cisplatin as shown in Figure. The resulting cisplatin allows platinum to bind with one or 
two nucleotide base depending on the extend of hydrolysis it went through. The 
attraction between DNA and activated cisplatin is also contributed by the opposite 





CONCLUSION AND RECOMMENDATION 
 
 The hyaluronan-cisplatin conjugation could be the answer to improve drug 
delivery system through targeted delivery by CD44 signaling. Based on the outcomes of 
this project, three dimensional molecular modeling of hyaluronan-cisplatin was 
successfully generated using Discovery Studio 2.5. In addition, the hyaluronan-cisplatin 
conjugate also improve water solubility of cisplatin. Through targeted delivery, cisplatin 
toxic effect on cancer cell increases while its effect on normal cells is minimized. It was 
also identified that cisplatin cytotoxicity is delivered by binding itself on DNA causing 
the DNA to be kinked and loses its ability to proliferate as well as promoting cell death. 
 
Recommendation and future work to improve the efficiency and to gain better 
insight of the project are stated as follow; 
 Correlates the simulation with lab results.  
 Preparation of CD44 and DNA structure if possible. 
 Further discussion of the approach in molecular level by applying organic 
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